On February 17, 2026, Canyon Capital Advisors reported in a Securities and Exchange Commission (SEC) filing that it sold all 521,774 shares of Acadia Healthcare (NASDAQ:ACHC) in the fourth quarter. What happened According to a filing with the Securities and Exchange Commission dated February 17, 2026, Canyon Capital Advisors fully exited its position in Acadia Healthcare by selling 521,774 shares. The quarter-end position value decreased by approximately $12.92 million as a result. What else to know T ...

Volume: ramping the 2,500 beds added over the last three years and bringing new beds online more efficiently.Osteen said her focus in returning to the CEO role is to build a strong company centered on excellence in patient care while also creating shareholder value. She laid out four key areas of focus:She also pointed to payer and geographic diversification, noting that 57% of payers are Medicaid across service lines and that no single state represents more than 15% of revenue .Osteen described Acadia as a ...

PresentationJohn RansomRaymond James & Associates, Inc., Research Division [ Good morning ], everybody. John Ransom. Welcome to our 47th IIC. I've been told I have to say that every time. So you'll get used to hearing that. In a very well-timed sequence of events, we have the returning CEO of ACHC, who made a lot of news last week. You can pull up the chart and see how the stock traded. This is Debbie's second time to have to come back to clean up a mess that she didn't make. So she knows how to do it. And ...

Acadia Healthcare Company (NasdaqGS:ACHC) FY Conference Summary Company Overview - Acadia Healthcare is a leading provider in the behavioral health sector, with a revenue of **$3.3 billion** for the full year of **2025** and treating **84,000 patients daily** [6][15] - The company operates **277 facilities** across **40 states**, with a diverse service offering including acute care, specialty services, residential treatment centers, and outpatient clinics [6][7] Core Business Insights - **Service Line Revenue**: - Acute care is the largest service line, contributing **70%** of revenue - Specialty services and outpatient clinics each account for **17%** of revenue - **57%** of payers are Medicaid [7][8] - **Patient Care Focus**: - Emphasis on improving patient care outcomes and safety, with ongoing investments in technology and staff training [8][9][12] - The company has added **2,500 new beds** over the last three years, with an additional **400-600 beds** expected in **2026** [10][18] Financial Performance and Projections - **Q4 Performance**: - Achieved **3.1% same-store volume growth**, an acceleration from Q3 [16] - Revenue guidance for **2026** is projected between **$3.37 billion** and **$3.45 billion**, with adjusted EBITDA between **$575 million** and **$610 million** [16][18] - **Challenges**: - Anticipated **350 basis point headwind** to same-store growth due to New York Medicaid restrictions [17] - A significant reduction in capital expenditures (CapEx) of over **$300 million** from **2025 to 2026** as new facilities are finalized [18] Operational Strategy - **Operational Excellence**: - Focus on enhancing payer relationships and ensuring appropriate reimbursement [11] - Emphasis on capital discipline and expense management for sustainable growth [11][12] - **Workforce Development**: - Aiming to recruit, retain, and train qualified staff, with improved retention rates noted [12][13] Legal and Compliance Considerations - **Malpractice Expenses**: - **$115 million** in malpractice expenses for **2025**, projected to decrease to **$100 million-$110 million** in **2026** [33] - Increased insurance costs and higher self-retention levels noted, with a focus on monitoring claims and settlements [34] Quality and Safety Initiatives - **Quality Metrics**: - Implementation of real-time tracking for incidents and outcomes at facilities to enhance patient safety [35][36] - Continuous investment in staff training to ensure high-quality patient care [38] Market Dynamics - **Demand for Services**: - Strong ongoing demand for behavioral health services, with a noted shortage of resources to meet patient needs [20] - **Outpatient Services**: - The company is focusing on expanding outpatient services, which are seen as essential for patient progression after stabilization [52][57] Conclusion - Acadia Healthcare is positioned for growth with a strong focus on operational execution, patient care, and strategic investments in facilities and workforce. The company faces challenges from regulatory changes and market dynamics but remains committed to enhancing shareholder value through improved patient outcomes and operational efficiency.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35331 ACADIA HEALTHCARE COMPANY, INC. (Exact name of registrant as specified in its charter) Delaware 45-2492228 (State or other jur ...

Core Viewpoint - Acadia Healthcare Company, Inc. is a prominent provider in the inpatient behavioral health care sector, focusing on delivering quality services while aiming for financial growth [1] Financial Performance - In Q4 2025, Acadia reported adjusted earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, resulting in an earnings surprise of over 164% [2][6] - Despite the earnings surprise, the company's profit declined by 89% year-over-year, while total revenues reached $821.5 million, reflecting a 6.1% increase compared to the previous year, surpassing the expected $799 million [3][6] - The revenue growth was attributed to a 3.1% increase in patient days and a 2.5% rise in admissions, leading to a 4.4% increase in same-facility revenues [3] Future Projections - Acadia anticipates revenues for 2026 to be between $3.37 billion and $3.45 billion, with adjusted EBITDA projected to range from $575 million to $610 million [4][6] - The company's projections indicate a strategic focus on service expansion and operational efficiency optimization, despite challenges such as a decrease in average length of stay and rising expenses [4] Stock Performance - Currently, ACHC's stock price is $21.48, reflecting a 3.09% increase, with fluctuations between a low of $20.88 and a high of $22.27 during the trading day [5] - Over the past year, the stock has seen a high of $42.85 and a low of $11.43, with a market capitalization of approximately $1.94 billion [5]

Core Viewpoint - Acadia Healthcare is a leading provider in the inpatient behavioral health care sector, recognized for its strong performance and unique market position [1]. Financial Performance - In the fourth quarter, Acadia reported adjusted earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.03, resulting in an earnings surprise of +164.15%. This is a decrease from $0.64 per share in the same quarter last year, but the company has consistently surpassed consensus EPS estimates over the last four quarters [3]. - Total revenues for the quarter reached $821.5 million, surpassing the expected $799 million, marking a 6.1% year-over-year increase driven by higher patient days and admissions, as well as increased revenues per patient day. However, this growth was partially offset by a shorter average length of stay and increased expenses [4]. Future Outlook - Acadia anticipates 2026 revenues to be between $3.37 billion and $3.45 billion, with adjusted EBITDA projected to range from $575 million to $610 million [5][6]. - Following the announcement of its fourth-quarter and full-year 2025 results, Acadia's stock experienced a 23% surge, benefiting from a broader market upswing, with a market capitalization of approximately $2 billion [5]. Analyst Ratings - Raymond James maintained an "Outperform" rating for Acadia Healthcare, indicating confidence in the company's future performance despite a recommendation to "hold" the stock [2][6].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights on product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-specific analyses for major pharmaceutical companies [1]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]

Core Insights - Acadia Healthcare Company, Inc. (ACHC) reported adjusted fourth-quarter earnings of 7 cents per share, exceeding the Zacks Consensus Estimate of 3 cents, but reflecting an 89% decline year over year [1] - Total revenues increased by 6.1% year over year to $821.5 million, surpassing the consensus mark of $799 million [1] Financial Performance - Same-facility revenues reached $792.7 million, a 4.4% increase year over year, beating the Zacks Consensus Estimate by 0.4% [3] - Patient days increased by 3.1%, while admissions grew by 2.5% year over year [3] - Average length of stay rose by 0.6% year over year, exceeding the consensus estimate [3] - Overall facility patient days improved by 4.5% year over year, with admissions growing by 7.2% [4] - Revenue per patient day increased by 1.5% year over year, while average length of stay declined by 2.5% [4] - Total expenses rose to $2 billion from $736.2 million in the prior-year period, driven by higher salaries, wages, benefits, and other operating costs [4] - Total adjusted EBITDA declined by 34.8% year over year to $99.8 million [4] Cash and Debt Position - As of December 31, 2025, Acadia Healthcare had cash and cash equivalents of $133.2 million, up from $76.3 million at the end of 2024 [5] - Long-term debt increased to $2.5 billion from $1.9 billion as of December 31, 2024 [6] - Total equity decreased to $1.9 billion from $3.1 billion at the end of 2024 [6] Share Repurchase and Full-Year Update - The company repurchased shares worth approximately $50 million in 2025 [7] - For the full year 2025, revenues rose by 5% year over year, with adjusted EPS declining to $2 per share from $3.30 [8] Future Guidance - For Q1 2026, revenues are projected to be between $820 million and $830 million, with adjusted EBITDA estimated at $130-$137 million [10] - For the full year 2026, revenues are expected to range from $3.37 billion to $3.45 billion, with adjusted EBITDA between $575 million and $610 million [11] - Adjusted EPS for 2026 is predicted to be between $1.30 and $1.55 [11] - Management estimates bed additions between 400 and 600 in 2026 [12]